News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Eli Lilly's Phase 3 trial shows retatrutide 12 mg delivered an average 28.3% body-weight reduction in the 80-week TRIUMPH-1 study.
  • Rising jet-fuel costs tied to the Middle East conflict are causing airlines to delay aircraft option exercises and raising insolvency risks, IATA and Embraer warn.
  • The U.S. is considering using frozen Iranian assets to fund Gulf infrastructure rebuilding after recent regional conflict.
  • Large credit managers are buying AI-linked debt structured to withstand potential credit strain from heavy corporate AI and data-center investment.
  • Southwest outlines product and network changes ahead of the 737 MAX 7's expected 2027 entry, including Starlink Wi‑Fi and upgraded premium seating.
  • White House AI adviser Sriram Krishnan will step down at the end of June and transition to an outside advisory role.

Latest Articles

Wall Street's Top Bull Signals Short-Term Caution Amid Record S&P Levels

Wall Street's Top Bull Signals Short-Term Caution Amid Record S&P Levels

Yardeni Research, which holds the highest year-end S&P 500 target on Wall Street at 8,250, says it is adopting a cautious stance on equities in the near term even as the S&P 500 surpassed 7,600 for the first time. The firm flagged a set of near-term risks - an unresolved Middle East conflict, warnings from major oil executives about low inventories…

Novo Nordisk: Deep Value Buy Ahead of a 2027 Growth Rebound

Novo Nordisk: Deep Value Buy Ahead of a 2027 Growth Rebound

Novo Nordisk is trading at roughly $43 with a market cap near $193B and a P/E of ~10. The market has punished the stock for near-term pricing and competition in GLP-1 drugs, but fundamentals - recurring revenue from diabetes and obesity care, an expanding oral Wegovy adoption, and a healthy dividend - argue for a re-rating if growth normalizes in 2…

TransUnion Expands TruIQ™ Data Enrichment on Snowflake AI Data Cloud to Power Prescreen Credit Marketing Campaigns

TransUnion Expands TruIQ™ Data Enrichment on Snowflake AI Data Cloud to Power Prescreen Credit Marketing Campaigns

TransUnion announced an expansion of its TruIQ Data Enrichment platform integrated with the Snowflake AI Data Cloud to support prescreen credit marketing campaigns, enabling customers to access and activate enriched credit data more quickly and securely within their own Snowflake environments. This new capability reduces campaign activation time fr…

AT&T: Deep Value, Growing FCF, and a Clear Path to Re-rating

AT&T: Deep Value, Growing FCF, and a Clear Path to Re-rating

AT&T trades at single-digit earnings multiples with a healthy free cash flow profile, a roughly 4.5% dividend yield, and a $19 billion California fiber commitment that demonstrates capital allocation toward durable growth assets. We present a long trade with disciplined risk controls that targets a meaningful multiple expansion while capturing inco…

Diginex Provides Update on Proposed Resulticks Acquisition

Diginex Provides Update on Proposed Resulticks Acquisition

Diginex Limited announced the extension of the long stop date to June 12, 2026 for its proposed acquisition of Resulticks Global Companies Pte. Limited. The acquisition aims to significantly expand Diginex's platform by integrating ESG data with real-time decisioning and customer engagement capabilities. Resulticks is expected to bring approximatel…

RadNet Announces a Proposed $200 Million Incremental Term Loan to Fund Strategic Growth Opportunities

RadNet Announces a Proposed $200 Million Incremental Term Loan to Fund Strategic Growth Opportunities

RadNet, Inc., a leading US outpatient diagnostic imaging provider, announced its intention to secure a $200 million incremental term loan. This funding aims to support future acquisitions, organic expansion, health system partnerships, and other corporate purposes to accelerate strategic growth across its national imaging network and technology pla…

New Expert Consensus Provides Age-Specific Guidance for Improving Care for Individuals with Genital Psoriasis Published in the American Journal of Clinical Dermatology

New Expert Consensus Provides Age-Specific Guidance for Improving Care for Individuals with Genital Psoriasis Published in the American Journal of Clinical Dermatology

Arcutis Biotherapeutics announces publication of a new expert consensus manuscript in the American Journal of Clinical Dermatology offering age-specific guidance for diagnosis and management of genital psoriasis across pediatric, adult, and older populations. The paper promotes routine genital assessment, empathetic communication, and individualize…

Celularity Appoints Rick Gonzalez as Chief Commercial Officer

Celularity Appoints Rick Gonzalez as Chief Commercial Officer

Celularity Inc., a US-based regenerative and cellular medicine company, announced the appointment of Rick Gonzalez as Chief Commercial Officer. Gonzalez brings extensive leadership experience in biotechnology and healthcare commercialization, supporting Celularity's efforts to advance its placental-derived cellular therapies, including cenplacel-L …

Rent the Runway, Inc. Announces First Quarter 2026 Results

Rent the Runway, Inc. Announces First Quarter 2026 Results

Rent the Runway, Inc. announced its Q1 fiscal 2026 results, achieving $89.9 million in revenue, up 29.2% year-over-year, exceeding guidance. The company showed improvement in EBITDA margin and add-on revenue increased by 70.4% YoY. New interim leadership appointments were made, and the company highlighted AI-driven personalization enhancements to i…

Twin Disc to Present at Three Part Advisors Ideas Conference

Twin Disc to Present at Three Part Advisors Ideas Conference

Twin Disc, Inc., a manufacturer of marine and heavy-duty off-highway power transmission equipment, announced that its CFO Jeff Knutson will present at the Three Part Advisors East Coast IDEAS Conference on June 10, 2026, in New York. The company also offers one-on-one investor meetings at the event, aiming to engage with institutional investors and…

Richtech Robotics Completes Strategic Acquisition of Warehouse Facility in Las Vegas to Accommodate Robotics and AI Powered Growth Objectives

Richtech Robotics Completes Strategic Acquisition of Warehouse Facility in Las Vegas to Accommodate Robotics and AI Powered Growth Objectives

Richtech Robotics Inc., listed on Nasdaq as RR, has completed the acquisition of a 79,325 square foot warehouse facility in Las Vegas for $21.2 million. This expansion is aimed at enhancing the company's AI infrastructure and robotics development, supporting its Industrial, Commercial, and Data Services strategic pillars. The facility will house GP…

Grayscale Investments Launches the Lowest Gross Fee Hyperliquid ETP in the U.S. with Grayscale® Hyperliquid Staking ETF (Ticker: HYPG)

Grayscale Investments Launches the Lowest Gross Fee Hyperliquid ETP in the U.S. with Grayscale® Hyperliquid Staking ETF (Ticker: HYPG)

Grayscale Investments has introduced the Grayscale Hyperliquid Staking ETF (HYPG) on Nasdaq, providing investors with exposure to the HYPE token of the Hyperliquid protocol along with staking rewards. As the lowest gross fee Hyperliquid ETP in the US, HYPG aims to offer a cost-efficient way to invest in a rapidly growing decentralized finance ecosy…

Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity

Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity

Biomea Fusion announces a new research collaboration with the University of Leicester to evaluate the combination of its investigational menin inhibitor, icovamenib, with semaglutide in overweight and obese individuals. This randomized double-blind study aims to determine if icovamenib can enhance weight loss while preserving lean mass and improvin…

Kyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, Treatment Refractory Rheumatoid Arthritis

Kyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, Treatment Refractory Rheumatoid Arthritis

Kyverna Therapeutics announced updated data from the Phase 1 portion of its COMPARE trial evaluating mivocabtagene autoleucel (miv-cel) in patients with active ACPA-positive, treatment-refractory rheumatoid arthritis. The data demonstrated deep B-cell depletion, sustained reduction in disease-associated autoantibodies, substantial reduction in dise…

Westwood Announces Monthly Income Distributions for Westwood Salient Enhanced Midstream Income ETF (MDST),Westwood Salient Enhanced Energy Income ETF (WEEI) and Westwood Enhanced Income Opportunity (YLDW)

Westwood Announces Monthly Income Distributions for Westwood Salient Enhanced Midstream Income ETF (MDST),Westwood Salient Enhanced Energy Income ETF (WEEI) and Westwood Enhanced Income Opportunity (YLDW)

Westwood Holdings Group (NYSE: WHG) disclosed monthly income distributions for three ETFs—Westwood Salient Enhanced Midstream Income ETF (MDST), Westwood Salient Enhanced Energy Income ETF (WEEI), and Westwood Enhanced Income Opportunity (YLDW). These actively managed funds provide monthly income through a combination of dividends and covered call …

Spyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpA

Spyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpA

Spyre Therapeutics has completed enrollment for all sub-studies in its SKYWAY basket trial evaluating SPY072, an anti-TL1A antibody, across rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA). The company reaffirms expected clinical data readouts in Q3 2026 for RA and Q4 2026 for PsA and axSpA, supporting poten…

CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer

CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer

CytomX Therapeutics has expanded its collaboration with Regeneron Pharmaceuticals to advance conditionally activated bispecific immunotherapies utilizing CytomX's PROBODY platform and Regeneron's Veloci-Bi technology. The expanded deal includes a $37 million target selection payment and potential milestones totaling approximately $4 billion as Rege…